Skip to content
Screener

Halozyme Therapeutics HALO D&A

D&A at other companies

West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
$45.7M+12.0%
AMP
Amphastar PharmaceuticalsAMPH
$8.04M-3.7%
AptarGroup logo
AptarGroupATR
$64.31M+17.1%
Opko Health logo
Opko HealthOPK
$22.41M-2.7%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$113K-18.7%
TriSalus Life Sciences, Inc. logo
TriSalus Life Sciences, Inc.TLSI
$135K-21.5%

Other financials

Income statement

See full
Revenue$481.0M+47.7%
Gross profit$401.8M+43.8%
Operating income$287.7M+42.1%
Net income$229.9M+39.2%
EPS (diluted)$1.90+42.9%

Balance sheet

See full
Cash & equivalents$164.0M+165%
Total debt$2.2B+41.6%
Total equity$143.5M-56.9%
Total assets$2.6B+25.5%

Cash flow

See full
Operating cash flow$240.9M+142%
CapEx$4.2M+167%
Free cash flow$236.7M+141%

Valuation

See full
Market cap$10.17B+39.6%
Enterprise value$12.19B+39.0%
P/E14.1×-4.1×
P/S6.1×-0.1×

Profitability

See full
Gross margin82.4%-1.8pp
Operating margin59.3%+9.0pp
Net margin47.9%+6.5pp
FCF margin48.5%+2.6pp

Returns & leverage

See full
Return on equity124.5%+12.7pp
Debt / equity15.2×+10.6×
Current ratio2.7×-5.7×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001159036-26-000104

FAQ

What is Halozyme Therapeutics's D&A?
Halozyme Therapeutics (HALO) reported D&A of $4.5M in Q2 2026.
How has Halozyme Therapeutics's D&A changed year-over-year?
Halozyme Therapeutics's D&A increased by 66.7% year-over-year, from $2.7M to $4.5M.
What is the long-term trend for Halozyme Therapeutics's D&A?
Over 4 years (2021 to 2025), Halozyme Therapeutics's D&A has grown at a 39.5% compound annual growth rate (CAGR), from $3.01M to $11.39M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Ask your AI about Halozyme Therapeutics's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude